Literature DB >> 20082484

Leukocyte-technetium-99m uptake in Crohn's disease: does it show subclinical disease?

Luciene G Mota1, Luiz G V Coelho, Carlos J R Simal, Maria L A Ferrari, Clodomiro Toledo, Josep Martin-Comin, Simone O F Diniz, Valbert N Cardoso.   

Abstract

AIM: To evaluate inflammatory activity in patients with Crohn's disease (CD) using technetium-99m-hexamethylpropyleneamine oxime (99mTc-HMPAO) granulocyte scintigraphy.
METHODS: Twenty patients (7 male and 13 female) with CD and five healthy volunteers were selected for 99mTc-HMPAO granulocyte scintigraphy. The Crohn's Disease Activity Index (CDAI), blood tests and C-reactive protein (CRP) of each patient were performed 7 d before the scintigraphic images. The leukocytes were labeled according to the International Society of Radiolabeled Blood Elements (ISORBE) consensus protocol and the scintigraphic images, including single photon emission computed tomography, were obtained 30 min and 2 h after injection of the radiolabeled leukocytes.
RESULTS: The labeling yield of the leukocytes with the lipophilic complex 99mTc-HMPAO was 55.0% +/- 10%. Six of the 20 patients (30%) presented congruent results for the three parameters investigated (CDAI, Scintigraphic Index and CRP). On the other hand, 14 patients (70%) did not show congruent results. There was no significant correlation between the indices analyzed according to the Spearman test (P > 0.05, n = 20).
CONCLUSION: The results suggest that 99mTc-HMPAO-labeled leukocyte scintigraphy could be important for determining inflammatory activity in CD even in the absence of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082484      PMCID: PMC2807959          DOI: 10.3748/wjg.v16.i3.365

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 2.  Role of scintigraphy in inflammatory bowel disease.

Authors:  Maria I Stathaki; Sophia I Koukouraki; Nikolaos S Karkavitsas; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

3.  A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE)

Authors:  M Roca; J Martín-Comín; W Becker; M Bernardo-Filho; B Gutfilen; A Moisan; M Peters; E Prats; M Rodrigues; C Sampson; A Signore; H Sinzinger; M Thakur
Journal:  Eur J Nucl Med       Date:  1998-07

4.  Inflammatory bowel disease activity assessment using technetium-99m-HMPAO leukocytes.

Authors:  J W Arndt; M I Grootscholten; R A van Hogezand; G Griffioen; C B Lamers; E K Pauwels
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

5.  111In-oxine-labelled autologous leucocytes in inflammatory bowel disease: new scintigraphic activity index.

Authors:  A Ybern; J Martin-Comin; J J Giné; T Casanovas; R Villa; M A Gassull
Journal:  Eur J Nucl Med       Date:  1986

Review 6.  Imaging infection/inflammation in the new millennium.

Authors:  H J Rennen; O C Boerman; W J Oyen; F H Corstens
Journal:  Eur J Nucl Med       Date:  2001-02

7.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

8.  Prospective comparative study of technetium-99m-WBCs and indium-111-granulocytes for the examination of patients with inflammatory bowel disease.

Authors:  J W Arndt; A van der Sluys Veer; D Blok; G Griffoen; H W Verspaget; C B Lamers; E K Pauwels
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

9.  99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.

Authors:  Alessio Annovazzi; Livia Biancone; Renato Caviglia; Marco Chianelli; Gabriela Capriotti; Stephen J Mather; Renzo Caprilli; Francesco Pallone; Francesco Scopinaro; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236

10.  Clinical experience with 99mTc-hexamethylpropylene-amineoxime for labelling leucocytes and imaging inflammation.

Authors:  A M Peters; H J Danpure; S Osman; R J Hawker; B L Henderson; H J Hodgson; J D Kelly; R D Neirinckx; J P Lavender
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

View more
  2 in total

1.  Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.

Authors:  Federico Caobelli; Laura Evangelista; Natale Quartuccio; Demetrio Familiari; Corinna Altini; Angelo Castello; Mariapaola Cucinotta; Rossella Di Dato; Cristina Ferrari; Aurora Kokomani; Iashar Laghai; Riccardo Laudicella; Silvia Migliari; Federica Orsini; Salvatore Antonio Pignata; Cristina Popescu; Erinda Puta; Martina Ricci; Silvia Seghezzi; Alessandro Sindoni; Martina Sollini; Letterio Sturiale; Anna Svyridenka; Vittoria Vergura; Pierpaolo Alongi
Journal:  World J Radiol       Date:  2016-10-28

2.  The Usefulness of Scintigraphic Studies in the Assessment of Asymptomatic Bowel Disease in Patients with Primary Antibody Diseases.

Authors:  Cinzia Milito; Francesco Cinetto; Valentina Megna; Giuseppe Spadaro; Isabella Quinti; Mauro Liberatore
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.